Table 2.

Radiation therapy details for studies incorporating radiation therapy for the treatment of advanced stage Hodgkin lymphoma

Trial	Radiation fields	PET era	Radiation dose
UK Lymphoma Group LY094	Initial bulky disease (>1/3 transthoracic ratio or >10 cm outside of chest) or residual CT mass	No	Variable (minimum 30 Gy ranging to >39 Gy)
EORTC11	IFRT to all sites of originally involved nodal areas + extranodal sites with or without a boost	No	24 Gy to nodal sites if CR; 30 Gy (± 4-10 Gy boost) to nodal sites if PR; 18-24 Gy to extranodal sites
GHSG HD1212	Sites of initial bulky disease (defined as ≥5 cm) or residual disease ≥1.5 cm on CT; also bone lesions with instability risk; whole anatomic region encompassed in volume	No	30 Gy
GHSG HD157	RT for persistent postchemotherapy PET-avid mass ≥2.5 cm and bone lesions regardless of residual PET activity if instability/fracture risk; 1.5 cm margin used	Yes	30 Gy
ECOG E249614	Bulky disease (defined as mass greater than one-third of the maximum intrathoracic diameter on standing posteroanterior chest x-ray in ABVD arm; any pretreatment sites of disease >5 cm in Stanford V arm)	No	36 Gy
GITIL/FIL trial HD 060715	Bulky disease (defined as ≥5 cm)	Yes	30 Gy
FIL trial HD 0801 (abstract only)16	Bulky disease (any initial mass with diameter >5 cm)	Yes	Not yet reported

Abbreviations: CR = complete response, CT = computed tomography; ECOG = Eastern Cooperative Oncology Group; EORTC = European Organization for Research and Treatment; FIL = Fondazione Italiana Linfomi; IFRT = involved-field radiation therapy; GHSG = German Hodgkin Study Group; GITIL/FIL = Gruppo Italiano Terapie Innovative nei Linfomi/Fondazione Italiana Linfomi; PET = positron emission tomography, PR = partial response.